E-compared: Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet

Sponsor
Linkoeping University (Other)
Overall Status
Completed
CT.gov ID
NCT02449447
Collaborator
European Commission (Other)
150
1
2
28
5.4

Study Details

Study Description

Brief Summary

To asses the clinical effectiveness of blended cognitive behavior therapy (CBT): face-to-face and internet-based treatment for adults with Major Depressive Disorder (MDD) in primary care compared to treatment as usual.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive behavioral therapy
  • Other: Treatment as usual
N/A

Detailed Description

The study is part of a EU-project. Participants are recruited via regular routes from primary care settings. Following the Mini International Neuropsychiatric Interview (M.I.N.I.) participants will be randomly allocated to either blended treatment for 10 sessions/weeks or to treatment as usual. We will include 150 participants in total.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
European Comparative Effectiveness Research on Internet-based Depression in Sweden (E-compared) Treatment). A Randomized Controlled Trial Comparing Blended Internet and Face-to-face CBT Against Treatment as Usual
Actual Study Start Date :
Feb 1, 2015
Actual Primary Completion Date :
Jun 1, 2016
Actual Study Completion Date :
Jun 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Blended treatment

10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.

Behavioral: Cognitive behavioral therapy
CBT based on behavioral activation and cognitive therapy techniques including homework

Active Comparator: Treatment as usual

Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).

Other: Treatment as usual
Treatment as usual in primary care including antidepressants and counselling

Outcome Measures

Primary Outcome Measures

  1. Quick Inventory of Depressive Symptomatology Self-Report (QIDS [Change from baseline in symptoms of depression. Time Frame: 0, 3, 6 and 12 months]

    Symptoms of depression measured by the QIDS. The QIDS is a questionnaire that screens for depressive symptoms and assesses depression severity.

Secondary Outcome Measures

  1. EuroQol-5D (EQ-5D-5L) [Time Frame: 0, 3, 6 and 12 months]

    Quality of life will be assessed with the EQ-5D-5L (EuroQol). The EQ-5D-5L is a self-report questionnaire which measures health related quality of life.

  2. Client Satisfaction Questionnaire (CSQ-8) [Time Frame: 3 months (post treatment)]

    Patient's satisfaction with the treatment is assessed with Client Satisfaction Questionnaire (CSQ-8)

  3. Credibility and Expectancy Questionnaire (CEQ) [Time Frame: 3 months (post treatment)]

    Patients' expectancy of treatment will be assessed with the credibility and expectancy questionnaire (CEQ)

  4. System Usability Scale (SUS) [Time Frame: 3 months (post treatment)]

    Satisfaction with the internet platform will be evaluated with the system usability scale (SUS)

  5. Patient Health Questionnaire (PHQ-9) [Time Frame: 0, 3, 6 and 12 months]

    The PHQ-9 is a nine-item mood module that can be used to screen and to diagnose patients with depressive disorders.

  6. Working Alliance Inventory (WAI-SF) [Time Frame: 0 months ( three weeks after started treatment)]

    The therapeutic alliance between therapists and patient will be assessed with the short version of the Working Alliance Inventory (WAI-SF).

  7. Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P) [Time Frame: 0, 3, 6 and 12 months]

    Health service uptake and production loss due to illness will be measured with the Trimbos and iMTA Questionnaires on Costs Associated with Psychiatric Illness (TiC-P)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • depressive symptoms according to DSM-IV

  • have access to a computer with internet connection

  • have good knowledge of the Swedish language

Exclusion Criteria:
  • recent (during last 6 weeks) change in psychiatric medication

  • presently in any other psychological treatment

  • severe depression

  • suicidal ideation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Behavioral Sciences and Learning, Linköping University Linköping Östergötland Sweden 58183

Sponsors and Collaborators

  • Linkoeping University
  • European Commission

Investigators

  • Principal Investigator: Heleen Riper, PhD, VU University of Amsterdam

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gerhard Andersson, Professor, Linkoeping University
ClinicalTrials.gov Identifier:
NCT02449447
Other Study ID Numbers:
  • E-compared
First Posted:
May 20, 2015
Last Update Posted:
Sep 20, 2017
Last Verified:
Sep 1, 2017
Keywords provided by Gerhard Andersson, Professor, Linkoeping University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 20, 2017